BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fonio P, Discalzi A, Calandri M, Doriguzzi Breatta A, Bergamasco L, Martini S, Ottobrelli A, Righi D, Gandini G. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification. Radiol Med. 2017;122:713-721. [PMID: 28510807 DOI: 10.1007/s11547-017-0770-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Ni L, Huang X, Jiang S, Ma L, Luo J, Chen S. Endoscopic Treatment as the Rescue Therapy for Recurrent Bleeding after Transjugular Intrahepatic Portosystemic Shunt (TIPS). Gastroenterol Res Pract 2021;2021:6627837. [PMID: 34381501 DOI: 10.1155/2021/6627837] [Reference Citation Analysis]
2 Chen Q, Zhang Y, Yue ZD, Zhao HW, Wang L, Fan ZH, Liu FQ. High-mobility group protein B1: A predictive biomarker for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. J Hepatobiliary Pancreat Sci 2020;27:522-30. [PMID: 32463549 DOI: 10.1002/jhbp.770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lewis DS, Lee T, Konanur M, Ziegler C, Hall MD, Pabon-ramos WM, Suhocki PV, Smith TP, Kim CY, Choi SS, Ronald J. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology 2019;30:163-9. [DOI: 10.1016/j.jvir.2018.10.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
4 Praktiknjo M, Simón-talero M, Römer J, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, Llop E, Maurer MH, Zipprich A, Triolo M, Maleux G, Fialla AD, Dam C, Vidal-gonzález J, Majumdar A, Picón C, Toth D, Darnell A, Abraldes JG, López M, Jansen C, Chang J, Schierwagen R, Uschner F, Kukuk G, Meyer C, Thomas D, Wolter K, Strassburg CP, Laleman W, La Mura V, Ripoll C, Berzigotti A, Calleja JL, Tandon P, Hernandez-gea V, Reiberger T, Albillos A, Tsochatzis EA, Krag A, Genescà J, Trebicka J, Quiroga S, Yu D, Téllez L, Mandorfer M, Garcia-pagan JC, Berbel C, Ferrusquia J, Ble M, Garcia-criado MA, Belmonte E, Ney M, Margini C, Casu S, Murgia G, Ludwig C, Stangl F. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology 2020;72:1140-50. [DOI: 10.1016/j.jhep.2019.12.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 32.0] [Reference Citation Analysis]
5 de Wit K, Schaapman JJ, Nevens F, Verbeek J, Coenen S, Cuperus FJC, Kramer M, Tjwa ETTL, Mostafavi N, Dijkgraaf MGW, van Delden OM, Beuers UHW, Coenraad MJ, Takkenberg RB. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterol 2020;7:e000531. [PMID: 33372103 DOI: 10.1136/bmjgast-2020-000531] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Schindler P, Seifert L, Masthoff M, Riegel A, Köhler M, Wilms C, Schmidt HH, Heinzow H, Wildgruber M. TIPS Modification in the Management of Shunt-Induced Hepatic Encephalopathy: Analysis of Predictive Factors and Outcome with Shunt Modification. J Clin Med 2020;9:E567. [PMID: 32092979 DOI: 10.3390/jcm9020567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Seifert LL, Görlich D, Jansen C, Ortmann O, Schoster M, Praktiknjo M, Gu W, Schindler P, Köhler M, Maschmeier M, Wilms C, Meyer C, Schmidt HH, Wildgruber M, Trebicka J, Heinzow H. Evaluation of impact of elective invasive examinations in patients with transjugular intrahepatic portosystemic shunt in the long-term follow up. Z Gastroenterol 2021;59:24-34. [PMID: 33429447 DOI: 10.1055/a-1330-9867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:157-74. [DOI: 10.1016/j.cld.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
9 Khan A, Maheshwari S, Gupta K, Naseem K, Chowdry M, Singh S. Rate, reasons, predictors, and burden of readmissions after transjugular intrahepatic portosystemic shunt placement. J Gastroenterol Hepatol 2021;36:775-81. [PMID: 32710679 DOI: 10.1111/jgh.15194] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rashidi-Alavijeh J, Kahraman A, Gerken G, Theysohn JM, Willuweit K, Hoyer DP, Lange CM, Buechter M. Enzymatic liver function measured by LiMAx is superior to current standard methods in predicting transplant-free survival after TIPS implantation. Sci Rep 2021;11:13834. [PMID: 34226640 DOI: 10.1038/s41598-021-93392-5] [Reference Citation Analysis]
11 Cai W, Lin H, Qi R, Lin X, Zhao Y, Chen W, Huang Z. Psoas Muscle Density Predicts Occurrences of Hepatic Encephalopathy in Patients Receiving Transjugular Intrahepatic Portosystemic Shunts within 1 year. Cardiovasc Intervent Radiol 2021. [PMID: 34523022 DOI: 10.1007/s00270-021-02961-8] [Reference Citation Analysis]
12 Krishnamurthy P, Ahmad A. Successful treatment of recurrent hepatic encephalopathy with revision of transjugular intrahepatic portasystemic shunt and embolisation of splenorenal shunt. BMJ Case Rep 2021;14:e242368. [PMID: 34167979 DOI: 10.1136/bcr-2021-242368] [Reference Citation Analysis]
13 Wang Z, Wu YF, Yue ZD, Zhao HW, Wang L, Fan ZH, Zhang Y, Liu FQ. Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(5): 416-427 [PMID: 33584073 DOI: 10.3748/wjg.v27.i5.416] [Reference Citation Analysis]
14 Yanny B, Winters A, Boutros S, Saab S. Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. Clin Liver Dis 2019;23:607-23. [PMID: 31563214 DOI: 10.1016/j.cld.2019.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526-1547. [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
16 Luo SH, Chu JG, Huang H, Zhao GR, Yao KC. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy. World J Gastroenterol 2019; 25(9): 1088-1099 [PMID: 30862997 DOI: 10.3748/wjg.v25.i9.1088] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]